AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18283231 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program (among participants who improved balance)
Number of subjects: 191
Study 18283231 — intervention group
Group type: COMPARATOR
Intervention: Control activity (among participants who improved balance)
Number of subjects: 191
Study 16172826 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-dyed food
Number of subjects: 20
Study 16172826 — intervention group
Group type: COMPARATOR
Intervention: Regular nondyed food (yellow pudding and white skim milk)
Number of subjects: 20
Study 16172826 — intervention group
Group type: COMPARATOR
Intervention: Regular nondyed food
Number of subjects: 20
Study 14727947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study 14727947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus a statin (lovastatin, pravastatin, atorvastatin, or simvastatin)
Number of subjects: 0
Study 14727947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus a statin
Number of subjects: 0
Study 10540365 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pentastarch
Number of subjects: 32
Study 10540365 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 32
Study 7812579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP), n = 14
Number of subjects: 29
Study 7812579 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 15
Number of subjects: 29
Study 2101441 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus psychotherapy
Number of subjects: 50
Study 2101441 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 50
Study 441686 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage of fluphenazine enanthate
Number of subjects: 44
Study 441686 — intervention group
Group type: COMPARATOR
Intervention: Low dosage of fluphenazine enanthate
Number of subjects: 44
Study 31455589 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 210
Study 31455589 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills containing drospirenone
Number of subjects: 210
Study 31455589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 27490418 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (BAS)/Everolimus (EVR)
Number of subjects: 288
Study 27490418 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (r-ATG)/Everolimus (EVR)
Number of subjects: 288
Study 27490418 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab (BAS)/Mycophenolate Sodium (MPS)
Number of subjects: 288
Study 27490418 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab (BAS)/Everolimus (EVR) vs Basiliximab (BAS)/Mycophenolate Sodium (MPS)
Number of subjects: 288
Study 27490418 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (r-ATG)/Everolimus (EVR) vs Basiliximab (BAS)/Mycophenolate Sodium (MPS)
Number of subjects: 288
Study 25808940 — intervention group
Group type: EXPERIMENTAL
Intervention: RPV/FTC/TDF
Number of subjects: 476
Study 25808940 — intervention group
Group type: COMPARATOR
Intervention: PI + RTV + 2NRTIs
Number of subjects: 476
Study 23786912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 162
Study 23786912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 21131631 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde pancreatography (ERP) in phase I
Number of subjects: 40
Study 21131631 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde pancreatography (ERP) in phase II
Number of subjects: 40
Study 19583605 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-coated circuits
Number of subjects: 30
Study 19583605 — intervention group
Group type: COMPARATOR
Intervention: Noncoated circuits (control group)
Number of subjects: 30
Study 17823681 — intervention group
Group type: EXPERIMENTAL
Intervention: Light curing the adhesive separately (Group PRC)
Number of subjects: 120
Study 17823681 — intervention group
Group type: COMPARATOR
Intervention: Co-curing the bonding agent with resin composite (Group COC)
Number of subjects: 120
Study 15183621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage (Shirodkar suture)
Number of subjects: 253
Study 15183621 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 253
Study 11529355 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) treatment: 250 mg ZDV orally twice a day starting at 38 weeks' gestation until labor, plus ZDV infusion at 2 mg/kg during the first hour of labor and then 1 mg/kg/h until delivery.
Number of subjects: 182
Study 11529355 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment: identical capsule during pregnancy and normal saline infusion during labor until delivery.
Number of subjects: 182
Study 9763051 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postnatal check-up (1 week after discharge)
Number of subjects: 683
Study 9763051 — intervention group
Group type: COMPARATOR
Intervention: Traditional postnatal check-up (6 weeks after birth)
Number of subjects: 683
Study 8853219 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate preceded by haloperidol
Number of subjects: 10
Study 8853219 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate preceded by placebo and then haloperidol
Number of subjects: 10
Study 2145656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (0.1 mumol)
Number of subjects: 7
Study 2145656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.15M NaCl)
Number of subjects: 7
Study 2145656 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms, 0.6 mumol)
Number of subjects: 7
Study 2145656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms, 0.1 mumol)
Number of subjects: 7
Study 7461330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid 'empiric' digitalization (group I)
Number of subjects: 454
Study 7461330 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow 'empiric' digitalization (group II)
Number of subjects: 454
Study 7461330 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Rational' digitalization (group III)
Number of subjects: 454
Study 7461330 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 'empiric' dosage followed by 'rational' maintenance (group IV)
Number of subjects: 454
Study 31888691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (Fear Reduction Efficacy Evaluation [FREE]) for 8 weeks, consisting of 8 weekly individual one-hour sessions.
Number of subjects: 50
Study 31888691 — intervention group
Group type: COMPARATOR
Intervention: Attention control group receiving diabetes self-management education (DSME) for 8 weeks, consisting of 8 weekly individual one-hour sessions.
Number of subjects: 50
Study 31888691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention (FREE)
Number of subjects: 50
Study 31888691 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (DSME)
Number of subjects: 50
Study 28382697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 12
Study 28382697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 26356708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU once daily
Number of subjects: 3746
Study 26356708 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) 5000 IU twice daily
Number of subjects: 3746
Study 23325376 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Choices
Number of subjects: 110
Study 23325376 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 110
Study 20435259 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BAP)
Number of subjects: 452
Study 20435259 — intervention group
Group type: COMPARATOR
Intervention: Bypass Surgery (BSX)
Number of subjects: 452
Study 20435259 — intervention group
Group type: COMPARATOR
Intervention: Bypass Surgery (BSX) with vein
Number of subjects: 452
Study 20435259 — intervention group
Group type: COMPARATOR
Intervention: Bypass Surgery (BSX) after failed BAP
Number of subjects: 452
Study 17600649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 498
Study 17600649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 17600649 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm guess
Number of subjects: 498
Study 17600649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion efficacy
Number of subjects: 498
Study 16636358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (2 mL)
Number of subjects: 83
Study 16636358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 83
Study 12748500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol replacement
Number of subjects: 43
Study 12748500 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol replacement
Number of subjects: 43
Study 12748500 — intervention group
Group type: COMPARATOR
Intervention: Control (no estradiol replacement)
Number of subjects: 43
Study 10978944 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg loperamide
Number of subjects: 19
Study 10978944 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg loperamide
Number of subjects: 19
Study 10978944 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg loperamide
Number of subjects: 19
Study 10978944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactase tablets
Number of subjects: 19
Study 10978944 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study 8595970 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5% twice a day (b.i.d.)
Number of subjects: 100
Study 8595970 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5% b.i.d. (6 months) alternated with 0.1% dipivefrin b.i.d. (2 months)
Number of subjects: 100
Study 8595970 — intervention group
Group type: EXPERIMENTAL
Intervention: dipivefrin
Number of subjects: 100
Study 1720485 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily
Number of subjects: 51
Study 1720485 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 51
Study 7034473 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 15 mg IV followed by a total daily dose of 200 mg/day
Number of subjects: 1395
Study 7034473 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395
Study 7034473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 31818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-isolating maneuver (LIM)
Number of subjects: 174
Study 31818160 — intervention group
Group type: COMPARATOR
Intervention: Lever-elevating maneuver (LEM)
Number of subjects: 174
Study 28673363 — intervention group
Group type: EXPERIMENTAL
Intervention: RYR-olive extract (10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per capsule)
Number of subjects: 50
Study 25308877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 30
Study 25308877 — intervention group
Group type: COMPARATOR
Intervention: Control group (age‐ and sex‐matched controls)
Number of subjects: 30
Study 23298376 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day for 14 days
Number of subjects: 38
Study 23298376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivasens
Number of subjects: 42
Study 21777097 — intervention group
Group type: EXPERIMENTAL
Intervention: BisBlock
Number of subjects: 42
Study 21777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 42
Study 21777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 42
Study 21777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE + Nd:YAG laser
Number of subjects: 42
Study 21777097 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study 19302635 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg.kg(‐1) bolus followed by 250 microg.kg(‐1)min(‐1) infusion)
Number of subjects: 60
Study 19302635 — intervention group
Group type: COMPARATOR
Intervention: Control group (no esmolol)
Number of subjects: 60
Study 17515571 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy only or nonalkylating chemotherapy (ABVD, EBVP)
Number of subjects: 355
Study 17515571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy containing alkylating agents (MOPP, ABV, BEACOPP)
Number of subjects: 355
Study 17515571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalkylating chemotherapy
Number of subjects: 355
Study 17515571 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkylating chemotherapy
Number of subjects: 355
Study 17515571 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of alkylating chemotherapy
Number of subjects: 355
Study 17515571 — intervention group
Group type: EXPERIMENTAL
Intervention: Age more than 50 years and stage II disease
Number of subjects: 355
Study 15504375 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 microg ethinyl estradiol (21)/180 microg norgestimate (7)
Number of subjects: 36
Study 15504375 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl estradiol (21)/150 microg desogestrel (21)
Number of subjects: 36
Study 15504375 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol (21)/100 microg levonorgestrel (21)
Number of subjects: 36
Study 11472042 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (open surgical or endovascular procedures)
Number of subjects: 264
Study 11472042 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise training
Number of subjects: 264
Study 11472042 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 264
Study 9492829 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-deoxy-5-fluorouridine (5'-DFUR) administration at a dose of 1,200 mg/body for 7 days
Number of subjects: 0
Study 8049831 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patch delivering 11 mg of nicotine over 24 hours
Number of subjects: 20
Study 8049831 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 20
Study 2839529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 17
Study 2839529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2839529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 17
Study 29288995 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto prevention program
Number of subjects: 6637
Study 29288995 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6637
Study 28747206 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 106
Study 28747206 — intervention group
Group type: COMPARATOR
Intervention: Vaginal sacrospinous fixation
Number of subjects: 106
Study 25500202 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g inulin-propionate ester
Number of subjects: 60
Study 25500202 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/day inulin-propionate ester supplementation
Number of subjects: 60
Study 25500202 — intervention group
Group type: COMPARATOR
Intervention: inulin-control group
Number of subjects: 60
Study 23363981 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 162
Study 23363981 — intervention group
Group type: COMPARATOR
Intervention: Control (no probucol treatment)
Number of subjects: 162
Study 21942491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-training evaluation and feedback (E&F group)
Number of subjects: 40
Study 21942491 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 40
Study 18436353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal immunization (0.1 ml of trivalent influenza vaccine)
Number of subjects: 34
Study 18436353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal immunization
Number of subjects: 34
Study 18436353 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunization (0.1 ml of trivalent influenza vaccine)
Number of subjects: 34
Study 18436353 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunization
Number of subjects: 34
Study 16520199 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 41
Study 16520199 — intervention group
Group type: COMPARATOR
Intervention: Conventional exposure
Number of subjects: 41
Study 14510756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic low osmolar agent
Number of subjects: 37
Study 14510756 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic, iso-osmotic agent
Number of subjects: 37
Study 14510756 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic, low osmolar agent
Number of subjects: 37
Study 14510756 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic angiography
Number of subjects: 37
Study 14510756 — intervention group
Group type: COMPARATOR
Intervention: Coronary intervention
Number of subjects: 37
Study 11938857 — intervention group
Group type: EXPERIMENTAL
Intervention: Olium Psidium guajava (PG)
Number of subjects: 62
Study 11938857 — intervention group
Group type: COMPARATOR
Intervention: Gegen Qinlian decoction (Control)
Number of subjects: 62
Study 9351034 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 78
Study 9351034 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation
Number of subjects: 78
Study 8409106 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association (AHA) diet
Number of subjects: 3401
Study 8409106 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA diet
Number of subjects: 3401
Study 8409106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber AHA-type diet
Number of subjects: 3401
Study 3083851 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (350 mg intravenously)
Number of subjects: 13
Study 3083851 — intervention group
Group type: COMPARATOR
Intervention: Sodium salicylate (1200 mg daily for 3 days)
Number of subjects: 13
Study 3083851 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (60.7 mg kg‐1 for 8 days)
Number of subjects: 13
Study 3083851 — intervention group
Group type: COMPARATOR
Intervention: Sodium salicylate (52.6 mg kg‐1 for 8 days)
Number of subjects: 13
Study 3083851 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 13
Study 29898752 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and chemotherapy (Arms B and C)
Number of subjects: 50
Study 29898752 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Arm A)
Number of subjects: 50
Study 28115966 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut oil (15 g/day for three months)
Number of subjects: 100
Study 28115966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 24300222 — intervention group
Group type: EXPERIMENTAL
Intervention: Factsheet about pain management (with pretest)
Number of subjects: 120
Study 24300222 — intervention group
Group type: EXPERIMENTAL
Intervention: Factsheet about pain management (without pretest)
Number of subjects: 120
Study 24300222 — intervention group
Group type: COMPARATOR
Intervention: Control group (without pretest)
Number of subjects: 120
Study 24300222 — intervention group
Group type: COMPARATOR
Intervention: Control group (with pretest)
Number of subjects: 120
Study 24300222 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 120
Study 21958929 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve-mask (BVM)
Number of subjects: 74
Study 21958929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-limited, flow adaptive ventilator (MEDUMAT Easy CPR)
Number of subjects: 74
Study 21265206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hook needle knife treatment
Number of subjects: 60
Study 21265206 — intervention group
Group type: COMPARATOR
Intervention: Local-blocking (control)
Number of subjects: 60
Study 17935553 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1000 mg/day)
Number of subjects: 50
Study 17935553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15736119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low rate of insulin infusion (1.5 mU insulin/kg per minute)
Number of subjects: 30
Study 15736119 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate of insulin infusion (15 mU insulin/kg per minute)
Number of subjects: 30
Study 12137603 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI group (benazepril 10 mg/d)
Number of subjects: 131
Study 12137603 — intervention group
Group type: COMPARATOR
Intervention: Non-ACEI group (control)
Number of subjects: 131
Study 9450772 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 283
Study 9450772 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 283
Study 9450772 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (both dosages)
Number of subjects: 283
Study 9450772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 7609520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour excision plus continuous tamoxifen
Number of subjects: 77
Study 7609520 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 77
Study 2550045 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg oral)
Number of subjects: 0
Study 2550045 — intervention group
Group type: COMPARATOR
Intervention: Perindoprilat (2 mg intravenously)
Number of subjects: 0
Study 2550045 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg oral) and Perindoprilat (2 mg intravenously)
Number of subjects: 0
Study 4608503 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) therapy
Number of subjects: 2000